[vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

Atelerix Life Sciences controls the intellectual property around a robust family of novel opioid-related therapeutics:

[/vc_column_text][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

Three issued patents:

[/vc_column_text][vc_single_image image=”265″ img_size=”full” alignment=”center”][vc_empty_space][vc_column_text]

• U.S. 10,881,633 (2021); 10,543,187 B2 (2020); and 10,080,732 (2018) with additional patents pending
• Includes broad claims on therapeutic uses, novel compositions of matter, formulations, assays and processes for this entire new approach to opioid-related unmet medical needs
• Planned international scope through PCT filing
• Exclusive Option Agreement, Case Western Reserve University

[/vc_column_text][vc_empty_space][/vc_column][/vc_row]